{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The proportion of study participants alive and without hematologic, cytogenetic or molecular evidence of BCR/ABL-positive leukemia at 1 year","groups":[{"description":"Beginning after engraftment and blood counts recover (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO once daily until day 80 and then nilotinib PO twice daily on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO twice daily beginning after engraftment and blood counts recover until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Single Arm Nilotinib Relapse Prophylaxis"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Proportion alive without relapse among the total number of patients with minimal residual disease follow-up data","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Patients Alive With Out Relapse","type":"SECONDARY","unitOfMeasure":"Participants"}